Exploiting the measles vector platform for vaccines
Interviewee/Contributor
Erich Tauber
Organisation
Themis Bioscience GmbH
Research Directory
Convalescent plasma hope in SARS-CoV-2 crisis
Interviewee/ContributorPeter CharlishOrganisationMedNousBiotechs fare relatively well amidst share collapse
Interviewee/ContributorWilliam EllingtonOrganisationMedNousCOVID-19's logistical impact on advanced therapies
Interviewee/ContributorMatthew LakelinOrganisationTrakCel LtdSolving the viral vector bottleneck during a pandemic
Interviewee/ContributorGéraldine Guérin-PeyrouOrganisationPolyplus-transfection SAWhat patients really want: involvement
Interviewee/ContributorPierre MeulienOrganisationInnovative Medicines InitiativeScientists and industry mobilise against coronavirus
Interviewee/ContributorVictoria EnglishOrganisationMedNousLate-stage oncology pipeline is robust
Interviewee/ContributorBruno PagliaraOrganisationMedNousA meeting of minds at AstraZeneca
Interviewee/ContributorJosé BaselgaOrganisationAstraZeneca PlcGroundbreaking genomic study of cancer published
Interviewee/ContributorPeter CharlishOrganisationMedNous